AI-assisted, human-published
07/31/2024 /Funding Events
LTZ Therapeutics Secures Over $20M in Series A Financing for Myeloid Engager Pipeline
LTZ Therapeutics completes Series A financing round with over $20 million to advance Myeloid Engager pipeline for cancer and autoimmune disease treatment, bringing total funding to approximately $50 million. The company is dedicated to developing immunotherapies to enhance clinical outcomes.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com